FRA:MRK - Merck KGaA Stock Price, News, & Analysis

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Merck KGaA (FRA:MRK) Frequently Asked Questions

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What price target have analysts set for MRK?

22 Wall Street analysts have issued 12 month price objectives for Merck KGaA's stock. Their forecasts range from €72.00 to €125.00. On average, they anticipate Merck KGaA's share price to reach €98.81 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price. View Analyst Price Targets for Merck KGaA.

What is the consensus analysts' recommendation for Merck KGaA?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 1 sell rating, 12 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merck KGaA.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include MERCK KGAA/S (MKKGY), Valeant Pharmaceuticals Intl (VRX), Canopy Growth (WEED), Aurora Cannabis (ACB), STADA Arzneimittel (SAZ), Aphria (APHQF), Hikma Pharmaceuticals (HKMPY), Hikma Pharmaceuticals (HIK), Aphria (APH), MedReleaf (LEAF), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE) and Weed (BUDZ).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:

• Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 61)
• Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 50)
• Dr. Walter Galinat, Member of Exec. Board (Age 62)
• Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 53)
• Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 47)

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €92.64.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $10.07 billion. Merck KGaA employs 54,009 workers across the globe.

What is Merck KGaA's official website?

The official website for Merck KGaA is https://www.merckgroup.com/.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.